Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430888 | 0.86 | LMNA (0.41) | SCN9ASMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL19427307 | 0.85 | SCN9A (0.49) | SCN9ASMN1; SMN2MAPK1 | |
| SCHEMBL23677159 | 0.83 | SCN9A (0.41) | SCN9ASMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL23419193 | 0.82 | ACACB (0.43) | SCN9ASMN1; SMN2ALDH1A1IDH1 | |
| SCHEMBL15599157 | 0.79 | SMN1; SMN2 (0.39) | SCN9ASMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL17428846 | 0.79 | SSTR4 (0.45) | SCN9ASMN1; SMN2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL16770601 | 0.77 | SMN1; SMN2 (0.37) | SCN9ASMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL19083678 | 0.76 | CYP1A2 (0.46) | SMN1; SMN2LMNAKMT2AALDH1A1MAPK1 | |
| SCHEMBL16082402 | 0.76 | SCN9A (0.44) | SCN9ACYP3A4SCN5A | |
| SCHEMBL19083879 | 0.76 | CYP1A2 (0.43) | SCN9ASMN1; SMN2LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766858-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190112264-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112264-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1547/4885SMN1; SMN2 2412/4885LMNA 299/4885 |
| US-10766858-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, SULT2A1 | SCN9A 1547/4885SMN1; SMN2 2412/4885LMNA 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.